Cambridge Antibody Technology (CAT), in its second pivotal ('International' Phase III) clinical trial, found Trabio failed to meet the primary endpoint of improving the outcome of surgery for glaucoma. This result is consistent with the result of the first pivotal (European' Phase II/III) clinical trial, which was announced in November 2004.
CAT is now terminating further development of Trabio as a potential treatment for improving the outcome of glaucoma surgery, as indicated in November 2004. Also in November 2004, CAT announced that it would be minimising, from that time, all future costs in connection with Trabio development.
Peter Chambré, CEO of CAT, comments, "Given the results announced in November from the first Trabio trial, this is an outcome for which we have planned. We took the decision at that time to minimise all costs associated with this programme. We will focus our resources on product opportunities such as the AstraZeneca alliance, GC-1008 with Genzyme, and CAT-354, our proprietary asthma candidate."
CAT is a biopharmaceutical company using its proprietary technologies and capabilities in human monoclonal antibodies for drug discovery and drug development. Based near Cambridge, England, CAT currently employs around 280 people.
Trabio is a fully human monoclonal antibody that neutralises Transforming Growth Factor Beta 2 (TGFß2) - a protein produced in response to injury in the eye and believed to be responsible for the formulation of excessive scar tissue, which is the main reason for failure of glaucoma surgery.
Trabio has been developed by CAT as a potential treatment for improving outcomes in glaucoma filtration surgery (trabeculectomy).